The primary endpoint of the study is laminated safety glass at 30 days. Invasive medical procedures.formance criteria such as in-stent and in-segment late loss, binary restenosis and target lesion revascularization. Data from the study will be compared to historical controls of both bare and drug-eluting stents.
Of clinical follow-up at 30 days and 6 months angiographic results after six months using quantitative coronary angioplasty and intravascular ultrasound are reported.
‘This study shows how the biochemistry the biochemistry of cancer dissect, we can therapies that design within the critical pathways important important survival for cancer,’said Keith L. Director of the Institute and of Neurosurgery of Neurosurgery at Cedars-Sinai.As part of strategy of the enterprise, is Alkermes schedule additional preclinical studies ALKS 33 to any other central nervous system illnesses and has also embarked on a phase 1 trial of ALKS 29, a potential oral treatment of alcohol dependence , the open-label crossovers. Trial was designed pharmacokinetics the pharmacokinetics, safety and tolerance of ALKS 29 compared to oral control of the Company anticipates top-line top-line results of the study in the first half calendar year 2009.
29, starts clinical studies on ALKS 33, A Novel Oral molecular with potential usefulness line addiction and other CNS disorders.. Alkermes, Inc. today announced the commencement a Phase 1 trial of ALKS 33, an oral opioid modulator of for potential treatment of on addiction and others the central nervous system . ALKS 33 This company the first novel in, small molecule drug candidate is give the clinic. Said molecule based on academic expertise Alkermes ‘ at brain reward pathways well as of the enterprise clinical and commercial expertise in the field of addiction. In addition, Alkermes initiating the clinical pharmacokinetic study of about further discover ALKS 29, a potential oral treatment of alcohol dependence.